ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster Presentations: Basic Science 2022

P001 Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on the IL23/IFNg axis

P002 Glial cell line-Derived Neurotrophic Factor (GDNF) improves intestinal wound healing – A new target for IBD treatment?

P003 Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease

P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls.

P005 The solute carrier LC22A4/Organic Cation Transporter (OCTN)-1 as a novel Inflammatory Bowel Disease determinant at the microbe-host interface.

P006 MiR-192 is associated with stricturing phenotype in Crohn’s disease

P007 ORMDL proteins shape homeostasis in the intestinal epithelium by regulating endoplasmic reticulum architecture and autophagy

P008 Modulation of Wnt signaling via a Wnt mimetic improved epithelial healing without causing hyperplasia in a mouse colitis model

P009 Integrin-b7+ cytotoxic MAIT cells are expanded in the colon of Ulcerative Colitis patients, correlate with disease severity and are targeted by vedolizumab therapy.

P010 Adherent-Invasive Escherichia Coli strain O83:H1 induces inflammatory response in Crohn's disease

P011 New insights into the pathogenic potential and signalling network of NKG2D+ CD4+ T-cells in Crohn’s Disease

P012 The effect of Oncostatin M on human intestinal organoids

P013 A single cell approach reveals immune cell dynamics in Inflammatory Bowel Disease (IBD) and highlights association of CD8 intraepithelial lymphocytes (IELs) with response to vedolizumab treatment

P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission

P015 Detection of endoscopic lesions from limited quality annotations in colonoscopy videos

P016 Colonoids derived from UC patients retain higher transcriptional response to inflammatory triggers in-vitro, even after several passages

P017 Transcriptional characterization of lymphocytic colitis and comparison to collagenous colitis

P018 Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery

P019 GS-1069518 is a potent and selective small molecule α4β7 inhibitor

P020 Differential expression of miR-424-5p and miR-378c in stenotic and penetrating lessions of Crohn’s Disease associates with altered transcription of genes involved in vascular regulation

P021 Vitamin D receptor-dependent protective effect of moderate hypoxia in a mouse colitis model Running title: Hypoxia prevents mouse colitis through VDR

P022 Transcriptional biomarkers for vedolizumab therapy response in patients with moderate to severe Ulcerative Colitis.

P023 Prevalence of malnutrition, risk of malnutrition and quality of life among patients with Inflammatory Bowel Disease.

P024 CD40 and key CD40/CD154 pathway members are significantly upregulated in inflamed lesional IBD biopsies as shown by whole transcriptome AmpliSeq gene expression profiling and corresponding immunohistochemistry.

P025 A review of the newly implemented Inflammatory Bowel Disease dietetic service

P026 Inflammatory bowel disease does not preclude the presence of environmental enteropathy in Zambian adults

P027 Effects of anti-TNF and anti-α4β7 drugs on circulating monocytes migratory capacity in inflammatory bowel disease

P028 Inhibition of stromal glycolysis by targeting PFKFB3 decreases experimental colitis

P029 Expression of miR-21 in mucosal biopsies give clues to anti-TNF treatment non-response in IBD children and adults

P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas

P031 Intestinal lymphoepithelial interactions in Crohn's disease: modeling alphaE-beta7 and NKG2D blockade

P032 Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients

P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment

P034 DISRUPTive liquid biopsies in Inflammatory Bowel Disease (DISRUPT-IBD): Release of exosomal and molecular tissue signals by transabdominal ultrasound?

P035 An examination of resting state functional connectivity in patients with active Crohn’s disease

P036 Identification and functional analysis of stromal subsets in experimental IBD mouse models

P037 MicroRNA-31 and microRNA-200 family reflect disease activity in Crohn’s disease: results from the BIOMIR study

P038 Targeting the hepcidin-ferroportin axis with Nrf2 agonists to treat iron deficiency anaemia in Inflammatory Bowel Disease

P039 The role of α4β7+CLA+ ‘dual tropic’ T cells in inflammatory bowel disease

P040 Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON)

P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies

P042 Succinate promotes the conversion from white to beige adipose tissue in Crohn’s Disease

P043 3-oxo-C12:2, a Quorum Sensing molecule from the gut, exerts anti-inflammatory effects through a bitter taste receptor

P044 Enteric dopaminergic pathways in mouse and human intestinal inflammation

P045 TIGIT expression differentiates regulatory from inflammatory Th1* gut-homing effector CD4+ T cells in inflammatory bowel disease patients

P046 Effects of CB2 and TRPV1 stimulation on osteoclast overactivity induced by iron in pediatric inflammatory bowel disease

P047 Effect of infliximab and vedolizumab on M1 and M2 macrophages derived from THP-1 cells.

P048 Bridging the Gap Between Body and Soul: A Pilot Study Examining Inflammation and Depression / Anxiety in Inflammatory Bowel Disease Patients

P049 The treatment effect of tonsil-derived mesenchymal stem cells (T-MSCs) via regulating programmed death-1/programmed death ligand-1 (PD-1/PD-L1) in ulcerative colitis

P050 A comparison of the Gut Microbiota in Pregnant Women with and without Inflammatory Bowel Disease and Their Offspring in Hong Kong and United States

P051 IFNγ-macrophages could mediate EMT in Crohn’s disease through the WNT pathway

P052 Comparing T cell responses to food antigens in Inflammatory Bowel Disease patients and healthy donors

P053 The intestinal complement system and its role in dysregulation of the intestinal B-cell compartment in Crohn’s Disease patients

P054 LHFPL3-AS2 long non-coding (lncRNA) is reduced in mucosal biopsies of Crohn Disease, and its reduction in tissue culture disrupts epithelial polarity

P055 Factors from human mesenteric adipose tissue control intestinal stem cell differentiation and proliferation in vitro

P056 Local nanocarrier delivery of JAK1 siRNA for IBD treatment: an in vivo mouse model

P057 Mucosal microbiota adapts to ATF6-induced alterations in host lipid metabolism with prognostic value in colorectal cancer

P058 IL-36 signaling in Crohn’s disease – characterization of a patient with an IL36RA mutation

P059 Diet controls segmented filamentous bacteria in driving Crohn’s disease-like inflammation in TNFdeltaARE mice

P060 Unravelling the microbial-derived metabolic alterations in a T-bet-/- x RAG2-/- mouse colitis model

P061 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course

P062 31P MRS and MRI phenotyping of muscle metabolic quality in IBD fatigue

P063 Expression of the coinhibitory receptor TIGIT on memory CD4+ T cells is induced by TCR ligation and retinoic acid co-stimulation and is elicited during microbial colonization of the intestine.

P064 IMU-838, a Small Molecule DHODH Inhibitor in Phase 2 Clinical Trial for Ulcerative Colitis, Shows Potent Anti-inflammatory Activity in Cell-Culture-Based and In Vivo Systems

P065 Determination of the cytokine pattern of human colon organoids derived from Inflammatory Bowel Disease patients

P066 Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis

P067 Human intestinal CD103+SIRPα+ conventional dendritic cells from patients with Crohn´s disease prime IL-17+ T-cells.

P068 Discovery of IBD3540: A Novel Gut-Restricted Glutamate Carboxypeptidase II Inhibitor with Preclinical Anti-Colitis Activity

P069 Design and delivery of anti-oxidant inorganic complexes mimicking the superoxide dismutase for inflammatory bowel diseases treatment.

P070 Novel long-acting lipidated interleukin-22 normalises colonic inflammation in an acute DSS colitis model

P071 Intestinal CD8+ T cell exhaustion is linked to disease activity in ulcerative colitis

P072 Melanocortin MC3 and MC5 receptors expression is different according to colonic disease activity in Crohn’s Disease and Ulcerative Colitis biopsies: results from an immunohistochemical observational study.

P073 Eosinophil depletion partially protects from colonic inflammation, but increases colonic collagen deposition in a DSS colitis model

P074 SZN-1326 promotes colonic mucosal healing in an acute injury model of IBD by first accelerating epithelial regeneration and secondarily reducing inflammation

P075 Neutrophils prevent rectal bleeding in Ulcerative Colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis

P076 Patients with Inflammatory Bowel Disease show IgG immune responses towards disease-associated small intestinal bacteria

P077 Different granulocyte subsets are involved in the pathogenesis in Crohn’s disease fistula

P078 Vedolizumab Treatment of ex-vivo Human Ulcerative Colitis (UC) Explants Results in Altered Inflammatory Protein Secretion Profiles

P079 The expression of some circulating micro RNAs and serum Vitamin D levels in IBD patients

P080 ADS024 attenuates weight loss and decreases disease activity in DSS-induced colitis

P081 Therapeutic Drug Monitoring of infliximab in Crohn’s Disease: Cut-off points during maintenance therapy.

P082 The profibrogenic role of neutrophil extracellular traps in stenotic Crohn's disease: a new antifibrotic target?

P083 An integrative analysis of DNA methylation and RNA-Seq data in human adipose-stem cells of Crohn’s Disease patients with different clinical activity

P084 Secreted inflammatory protein profiles following treatment of ex-vivo human Ulcerative Colitis and Crohn’s Disease explants with licenced biologic therapies

P085 Paneth cells translate dietary lipid exposure into gut inflammation

P086 Mucosal microbiota modulate host intestinal immune signatures in Inflammatory Bowel Disease

P087 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Impact of Ulcerative Colitis Symptoms on Daily Life

P088 Metabolomic analysis reveals differences among UC and non-IBD human colonic resections: role of GPCRs

P089 Long ncRNA Landscape in the Rectum of Treatment Naïve Early Onset Ulcerative Colitis Highlights Association with Severity and Early and Late Disease Outcome, with Potential Role in Epithelial Metabolic Functions

P090 Unraveling the rewiring of cytokine signalling in Inflammatory Bowel Disease using a novel network biology approach

P091 A single-cell RNAseq approach to understand and predict the efficacy of tofacitinib in Ulcerative Colitis

P092 Humoral and T cell responses to COVID-19 vaccination in IBD

P093 Probiotic strains Lactobacillus plantarum and Saccharomyces boulardii influence the fibrotic responses of human intestinal subepithelial myofibroblasts.

P094 Transcriptomic and small RNA sequencing profile in ileal resections from complicated Crohn´s Disease patients

P095 Anti-inflammatory effect of high acetate concentration on organoid-derived epithelial monolayer from patients with Ulcerative Colitis

P096 Store-Operated Calcium Entry Controls Innate and Adaptive Immune Cell Function in Inflammatory Bowel Disease

P098 Mucosal Microbiota Composition Predicts Infliximab Response in Inflammatory Bowel Diseases

P099 Serum proteomic analysis reveals novel biomarkers associated with disease activity in pediatric patients with Crohn’s disease

P100 Serum inflammatory protein profiling to corroborate selection of therapy naïve moderate-to-severe pediatric Crohn’s disease patients eligible for first-line infliximab treatment

P101 Isosteviol Attenuates Dextran Sulfate Sodium-Induced Colitis by Maintaining the Intestinal Barrier Through PDK1/AKT/NF-κB Signaling

P102 Changes in serum immune protein profiles following vedolizumab therapy in Inflammatory Bowel Disease.

P103 Identifying CES-1 positive myeloid cells with mass cytometry as a potential therapeutic target for Crohn’s disease

P104 Icariin Attenuates Intestinal Inflammation through Inhibition of the Nuclear Factor-ĸB signaling

P105 Treatment of the lower gastrointestinal tract Klebsiella infections by recombinant bacteriocin KvarIa

P106 Macrophages as a source of NOTCH Ligands in Crohn's disease: implications in fibrosis

P107 IL10 secretion endows intestinal human iNKT cells with regulatory functions towards pathogenic T lymphocytes in Crohn's disease patients